Invention Grant
- Patent Title: Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity
-
Application No.: US15555500Application Date: 2016-03-03
-
Publication No.: US11325970B2Publication Date: 2022-05-10
- Inventor: Huawei Qiu , Julie Bird
- Applicant: GENZYME CORPORATION
- Applicant Address: US MA Cambridge
- Assignee: GENZYME CORPORATION
- Current Assignee: GENZYME CORPORATION
- Current Assignee Address: US MA Cambridge
- Agency: Steptoe & Johnson LLP
- Agent Z. Ying Li; Mauricio Alvarez
- International Application: PCT/US2016/020780 WO 20160303
- International Announcement: WO2016/141245 WO 20160909
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22
Abstract:
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.
Public/Granted literature
Information query
